Phase II trial of erlotinib (OSI-774), an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, and bevacizumab, a recombinant humanized monoclonal antibody to vascular endothelial growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback